[EN] BICYCLOHETEROARYLAMINE COMPOUNDS AS ION CHANNEL LIGANDS AND USES THEREOF [FR] COMPOSES BICYCLOHETEROARYLAMINE COMME LIGANDS DE CANAUX IONIQUES ET UTILISATIONS DESDITS COMPOSES
[EN] FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS PEST CONTROL AGENTS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES CONDENSÉS ET LEUR UTILISATION EN TANT QU'AGENTS DE LUTTE CONTRE LES NUISIBLES
申请人:PI INDUSTRIES LTD
公开号:WO2020178789A1
公开(公告)日:2020-09-10
The present invention discloses a fused heterocyclic compound of general formula (I), Formula (I) wherein, R1, R3, X, A, m and n are as defined in the detailed description. The present invention further discloses methods for their preparation and use of the fused heterocyclic compounds of general formula (I) as a pest control agent.
Tetrahydro-pyrimidoazepines as modulators of TRPV1
申请人:Allison D. Brett
公开号:US20070225275A1
公开(公告)日:2007-09-27
Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be-administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.
Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
申请人:Kelly G. Michael
公开号:US20050277643A1
公开(公告)日:2005-12-15
Amine compounds are disclosed that have a formula represented by the following:
The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, traumatic injury, and others.
TETRAHYDRO-PYRIMIDOAZEPINES AS MODULATORS OF TRPV1
申请人:Janssen Pharmaceutica NV
公开号:US20140135311A1
公开(公告)日:2014-05-15
Certain tetrahydro-pyrimidoazepine compounds are described, which are useful as TRPV1 modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by TRPV1. Thus, the compounds may be administered to treat, e.g., pain, itch, cough, asthma, or inflammatory bowel disease.